ATE431364T1 - Inhibitoren der menschlichen elastase von neutrophilen - Google Patents

Inhibitoren der menschlichen elastase von neutrophilen

Info

Publication number
ATE431364T1
ATE431364T1 AT03000399T AT03000399T ATE431364T1 AT E431364 T1 ATE431364 T1 AT E431364T1 AT 03000399 T AT03000399 T AT 03000399T AT 03000399 T AT03000399 T AT 03000399T AT E431364 T1 ATE431364 T1 AT E431364T1
Authority
AT
Austria
Prior art keywords
proteins
elastasis
inhibitors
human neutrophil
compositions
Prior art date
Application number
AT03000399T
Other languages
English (en)
Inventor
Arthur Charles Ley
Robert Charles Ladner
Sonia Kosow Guterman
Bruce Lindsay Roberts
William Markland
Rachel Baribault Kent
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/664,989 external-priority patent/US5223409A/en
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of ATE431364T1 publication Critical patent/ATE431364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Insects & Arthropods (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03000399T 1991-03-01 1992-02-28 Inhibitoren der menschlichen elastase von neutrophilen ATE431364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/664,989 US5223409A (en) 1988-09-02 1991-03-01 Directed evolution of novel binding proteins
US71583491A 1991-06-17 1991-06-17

Publications (1)

Publication Number Publication Date
ATE431364T1 true ATE431364T1 (de) 2009-05-15

Family

ID=27099103

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03000399T ATE431364T1 (de) 1991-03-01 1992-02-28 Inhibitoren der menschlichen elastase von neutrophilen
AT92908481T ATE243710T1 (de) 1991-03-01 1992-02-28 Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92908481T ATE243710T1 (de) 1991-03-01 1992-02-28 Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g

Country Status (9)

Country Link
EP (2) EP1325931B1 (de)
JP (1) JP3819931B2 (de)
AT (2) ATE431364T1 (de)
AU (1) AU1581692A (de)
CA (1) CA2105304C (de)
DE (3) DE573603T1 (de)
DK (1) DK0573603T3 (de)
ES (1) ES2124203T3 (de)
WO (1) WO1992015605A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
DK1820858T3 (da) 1991-03-01 2009-11-02 Dyax Corp Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf
US5478811A (en) * 1991-08-22 1995-12-26 Merrell Dow Pharmaceuticals Inc. Orally-active elastase inhibitors
US5714470A (en) * 1991-08-22 1998-02-03 Merrell Pharmaceuticals, Inc. Orally-active elastase inhibitors
JP2769083B2 (ja) * 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP4221059B2 (ja) * 1994-06-02 2009-02-12 アベンティス・インコーポレイテッド エラスターゼインヒビターのプロドラッグとしてのアシル化エノール誘導体
ES2137509T3 (es) * 1994-06-02 1999-12-16 Merrell Pharma Inc Perfluoroalquilcetonas, inhibidoras de elastasa y procedimientos para su preparacion.
EP0699750A1 (de) * 1994-06-07 1996-03-06 Gesellschaft für biotechnologische Forschung mbH (GBF) Eine Sammling an Phagemiden, eine Sammling von Escherichia coli Zellen die diese Phagemide tragen, eine Sammling an Phagemid-Partikeln die daraus hergestellt würden und Phagemid-Partikel die durch dieses Verfahren erhalten würden
JPH10506463A (ja) * 1994-09-21 1998-06-23 サイトーゲン コーポレーション ペプチドライブラリー由来の抗原結合性ペプチド（アブチド）
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US6172044B1 (en) 1995-12-01 2001-01-09 Aventis Pharmaceuticals Inc. Acylated enol derivative of α-ketoesters and α-ketoamides
US5948886A (en) * 1996-11-20 1999-09-07 Hoechst Marion Roussel, Inc. Acylated enol derivatives of α-ketoesters and α-ketoamides
HU226419B1 (en) 1996-03-11 2008-12-29 Aerovance Human bikunin
AR030257A1 (es) * 1998-12-22 2003-08-20 Bayer Ag Uso de un inhibidor de proteasa serina de tipo kunitz para la fabricacion de un medicamento para acelerar la velocidad de aclaramiento mucociliar
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
EP1201249A1 (de) * 2000-10-31 2002-05-02 Debiopharm S.A. Suspension von EPI-HNE-4, daraus hergestelltes Trockenpulveraerosol, Herstellungsverfahren und Arzneimittel enthaltend diese Suspension- oder Aerosolzubereitung und ihre Verwendung
CN100396329C (zh) * 2000-10-31 2008-06-25 德比奥药物股份有限公司 Epi-hne蛋白质悬浮液,其制备方法,其派生的干粉气溶胶,含有所述悬浮液或气溶胶的药物组合物及其应用
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
JP2008506391A (ja) * 2004-07-13 2008-03-06 バイエル・フアーマシユーチカルズ・コーポレーシヨン 改良されたアプロチニン変異体
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
JP5985826B2 (ja) 2008-12-16 2016-09-06 ノバルティス アーゲー 酵母ディスプレイ系
CN110055221B (zh) * 2019-04-16 2021-10-08 清华大学 一种基于细胞三维打印技术的类脑疾病治疗组织模型及其制备方法与应用
EP4031138A1 (de) 2019-09-17 2022-07-27 Mereo Biopharma 4 Limited Alvelestat zur verwendung bei der behandelung von transplantatabstossung, bronchiolitis-obliterans-syndrom und transplantat-gegen-wirtszelle
DK4106757T3 (da) 2020-04-16 2023-10-23 Mereo Biopharma 4 Ltd Fremgangsmåder der involverer neutrofil elastase-inhibitor alvelestat til behandling af luftvejssygdom medieret af alpha-1-antitrypsin-mangel
JP2024540952A (ja) 2021-10-20 2024-11-06 メレオ バイオファーマ ４ リミテッド 線維化の治療における使用のための好中球エラスターゼ阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
CA1341029C (en) * 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
EP1997891A1 (de) * 1988-09-02 2008-12-03 Dyax Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
EP0401508B1 (de) * 1989-05-13 1994-11-23 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel

Also Published As

Publication number Publication date
WO1992015605A3 (en) 1992-12-23
ATE243710T1 (de) 2003-07-15
WO1992015605A2 (en) 1992-09-17
JPH06510522A (ja) 1994-11-24
EP1325931B1 (de) 2009-05-13
DE69233760D1 (de) 2009-06-25
EP0573603B1 (de) 2003-06-25
DE69233108T2 (de) 2004-04-29
ES2124203T3 (es) 2004-04-16
EP1325931A1 (de) 2003-07-09
AU1581692A (en) 1992-10-06
DE573603T1 (de) 1999-05-06
CA2105304A1 (en) 1992-09-02
EP0573603A1 (de) 1993-12-15
JP3819931B2 (ja) 2006-09-13
DE69233108D1 (de) 2003-07-31
CA2105304C (en) 2005-10-04
DK0573603T3 (da) 2003-10-20
ES2124203T1 (es) 1999-02-01

Similar Documents

Publication Publication Date Title
ATE431364T1 (de) Inhibitoren der menschlichen elastase von neutrophilen
DE69427582D1 (de) Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
FI933770A7 (fi) Farmaseuttisia koostumuksia ihotautien hoitamiseen
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
LV11666A (lv) Farmaceitiskie preparati un medikamenti endotelialo traucejumu noversanai un arstesanai
DE69001686D1 (de) Behandlung von leukozytstoerungen mit gm-csf.
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
EP0373771A3 (de) Neue pharmazeutische Anwendungen von Cystatinen
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
NO990450L (no) Behandling av sinnslidelser
FI956353L (fi) Farmaseuttiset valmisteet ja niiden käyttö etenkin neurodegeneratiivisten sairauksien hoidossa
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
FI950649A7 (fi) Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet
FI961494L (fi) Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
ATE120956T1 (de) Pyrimido-benzothiazinderivate zur behandlung von entzündung, allergie and kardiovaskulären erkrankung.
FI900379A7 (fi) Uudet farmaseuttiset seokset ja uudet farmaseuttiset tuotteet, jotka sallivat leukosyyttien regeneroimisen ja niiden käyttö AIDS:in hoidossa
ITMI911930A1 (it) Composizioni farmaceutiche di stereoisomeri di ossiracetam e loro impiego terapeutico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties